AGC Pharma Chemicals Partners with Ability Pharma on Pancreatic Cancer API

• AGC Pharma Chemicals and Ability Pharma collaborate to develop ABTL0812, an API for pancreatic cancer treatment.

• The partnership aims to transition ABTL0812 from clinical trials to commercialisation, enhancing chemotherapy effects without increasing toxicity.

AGC Pharma Chemicals and Ability Pharma have announced a strategic collaboration to develop ABTL0812, an active pharmaceutical ingredient (API) for treating pancreatic cancer. The collaboration will leverage AGC Pharma Chemicals’ extensive experience in process optimisation and scale-up to bring ABTL0812 from the clinical phase to commercialisation.

AGC Pharma Chemicals, an international CDMO with facilities in Spain and Japan, will utilise its Kilo lab and GMP production line for the project. The company’s demonstrated capabilities in scaling up API production from grams to tonnes ensure the highest quality standards are maintained.

ABTL0812 is a promising therapy for pancreatic cancer, an orphan disease in need of effective treatments. It enhances the effects of various chemotherapies without increasing toxicity, showing improved overall response rates and progression-free survival in clinical trials. This collaboration will support AbilityPharma in advancing this innovative therapy from the laboratory to patients globally.

AGC Pharma Chemicals has maintained high pharmaceutical standards, as evidenced by its impeccable quality inspection record over the past 20 years. Additionally, the company’s commitment to sustainability, recognised with an EcoVadis Platinum rating, aligns with Ability Pharma’s values in responsible drug development practices.